EA
TCRT icon

Emerald Advisers’s Alaunos Therapeutics TCRT Stock Holding History

Emerald Advisers’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-82
Closed -$69K – 305
2016
Q3 		$69K Sell
82
-3,595
-98% -$2.89M ﹤0.01% 316
2016
Q2 		$3.03M Sell
3,677
-8
-0.2% -$8.71K 0.15% 169
2016
Q1 		$4.1M Sell
3,685
-174
-5% -$178K 0.2% 138
2015
Q4 		$4.81M Buy
3,859
+566
+17% +$936K 0.23% 130
2015
Q3 		$4.45M Sell
3,293
-59
-2% -$97.4K 0.23% 130
2015
Q2 		$6.03M Buy
3,352
+920
+38% +$1.43M 0.29% 109
2015
Q1 		$3.36M Buy
2,432
+675
+38% +$1M 0.17% 158
2014
Q4 		$1.34M Buy
+1,757
New +$933K 0.07% 225
2014
Q3 		– Sell
-12
Closed -$7K – 405
2014
Q2 		$7K Buy
+12
New +$6.68K ﹤0.01% 421

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Emerald Advisers's TCRT Position: Q4 2016 in Review

Emerald Advisers sold out of Alaunos Therapeutics (TCRT) in Q4 2016, closing a stake of 82 shares — an estimated $69K sold.

Emerald Advisers first reported a position in TCRT in Q2 2014 and held it in 9 quarters. The position peaked at $6.03M in Q2 2015. 136 funds tracked by Wall St. Rank hold TCRT as of Q4 2016.

  • Emerald Advisers reported no remaining Alaunos Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Emerald Advisers sold 82 Alaunos Therapeutics shares in Q4 2016, an estimated $69K.
  • Emerald Advisers first reported a position in Alaunos Therapeutics in Q2 2014 and held it in 9 quarters.
  • Emerald Advisers's Alaunos Therapeutics position peaked at $6.03M in Q2 2015.
  • 136 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2016.

Based on Emerald Advisers's 13F filing for Q4 2016, filed 26 Jan 2017.